NCT06356311 2026-02-27
TroFuse-015
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
Clinical Trials
17 trialsNCT05198934 2026-02-06
CodeBreak300
Amgen
Phase 3 Active not recruiting
NCT03844620 2026-01-09
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04564898 2026-01-08
TriComB
Gruppo Oncologico del Nord-Ovest
Phase 1/2 Active not recruiting
NCT05029882 2025-10-29
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie
Phase 1 Active not recruiting
NCT04104139 2025-10-27
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
NCT04489173 2025-09-19
TIBET
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT07142421 2025-08-26
A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma
First Affiliated Hospital of Zhejiang University
Phase 2 Active not recruiting
NCT07090031 2025-07-29
Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer
Qingdao Central Hospital
Phase 2 Active not recruiting
NCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT06199973 2025-07-17
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Active not recruiting
NCT05508737 2025-07-11
Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer
Yonsei University
Phase 1/2 Active not recruiting
NCT05854498 2025-06-12
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT03368963 2025-01-07
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
Phase 1/2 Active not recruiting
NCT04294264 2024-11-18
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT06403709 2024-09-24
Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT03992456 2024-05-21
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting